Gretchen L. Temeles, Ph.D. wrote: All in a day’s work at the PTAB: Post-grant review denied for psychedelic therapeutics patent-Schedule I status irrelevant In 2019, the Patent and Trial Appeal Board (PTAB) of the United States Patent and Trademark Office (USPTO) issued a decision in the first inter partes review of a cannabis related patent (Insys Development Company, Inc. v. GW Pharma Limited and Otsuk (More) | |
Gretchen L. Temeles, Ph.D. wrote: Patent protection of psychedelic therapeutics: a page from the cannabis playbook? As increasing numbers of U.S. states have legalized both medical and adult-use cannabis, another set of Schedule 1 controlled substances - psychedelics - has begun to emerge from the shadows. Psychedelics such as psilocybin, lysergic acid diethylamid (More) |
